Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGYP
CUSIP87163930
Phone212-297-0020
Debt
Debt-to-Equity Ratio-3.01
Current Ratio3.09
Quick Ratio2.71
Price-To-Earnings
Trailing P/E Ratio-1.85
Forward P/E Ratio-3.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.82 million
Price / Sales27.87
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-95.00
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-224,330,000.00
Net Margins-773.82%
Return on Equity-652.66%
Return on Assets-145.45%
Miscellaneous
Employees313
Outstanding Shares246,740,000
Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions
What is Synergy Pharmaceuticals' stock symbol?
Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."
How were Synergy Pharmaceuticals' earnings last quarter?
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced its earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company earned $8.59 million during the quarter, compared to the consensus estimate of $11.18 million. Synergy Pharmaceuticals had a negative net margin of 773.82% and a negative return on equity of 652.66%. Synergy Pharmaceuticals's revenue was up 776.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.30) EPS. View Synergy Pharmaceuticals' Earnings History.
What price target have analysts set for SGYP?
8 analysts have issued twelve-month price objectives for Synergy Pharmaceuticals' shares. Their forecasts range from $2.50 to $15.00. On average, they expect Synergy Pharmaceuticals' stock price to reach $8.8125 in the next twelve months. View Analyst Ratings for Synergy Pharmaceuticals.
What are Wall Street analysts saying about Synergy Pharmaceuticals stock?
Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (5/9/2018)
- 2. Cantor Fitzgerald analysts commented, "As we predicted in a report published last week, SGYP disclosed that the cash balance at the end of January exceeded the $128 million level required to access $100 million from the CRG Term Loan Agreement." (2/1/2018)
Are investors shorting Synergy Pharmaceuticals?
Synergy Pharmaceuticals saw a drop in short interest in the month of May. As of May 31st, there was short interest totalling 61,357,361 shares, a drop of 2.0% from the May 15th total of 62,620,901 shares. Based on an average daily volume of 2,608,186 shares, the days-to-cover ratio is presently 23.5 days. Approximately 24.9% of the shares of the company are sold short.
Who are some of Synergy Pharmaceuticals' key competitors?
Some companies that are related to Synergy Pharmaceuticals include Aimmune Therapeutics (AIMT), Myokardia (MYOK), Zogenix (ZGNX), Biohaven Pharmaceutical (BHVN), Mallinckrodt (MNK), TherapeuticsMD (TXMD), G1 Therapeutics (GTHX), Cambrex (CBM), ARMO Biosciences (ARMO), Myovant Sciences (MYOV), Pacira Pharmaceuticals (PCRX), Innoviva (INVA), Wave Life Sciences (WVE), Deciphera Pharmaceuticals (DCPH) and Amneal Pharmaceuticals (AMRX).
Who are Synergy Pharmaceuticals' key executives?
Synergy Pharmaceuticals' management team includes the folowing people:
- Dr. Gary S. Jacob, Exec. Chairman (Age 71)
- Mr. Troy Hamilton Pharm.D., CEO & Director (Age 46)
- Dr. Kunwar Shailubhai, Chief Scientific Officer and Exec. VP (Age 60)
- Dr. Patrick H. Griffin M.D., FACP, Exec. VP & Chief Medical Officer (Age 63)
- Mr. Gary G. Gemignani, Exec. VP & CFO (Age 53)
Has Synergy Pharmaceuticals been receiving favorable news coverage?
News articles about SGYP stock have trended somewhat positive recently, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a daily sentiment score of 0.03 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.62 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Synergy Pharmaceuticals' major shareholders?
Synergy Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.62%), Hikari Power Ltd (0.81%), JPMorgan Chase & Co. (0.74%), CVI Holdings LLC (0.72%), Schwab Charles Investment Management Inc. (0.50%) and UBS Group AG (0.47%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.
Which major investors are selling Synergy Pharmaceuticals stock?
Which major investors are buying Synergy Pharmaceuticals stock?
SGYP stock was acquired by a variety of institutional investors in the last quarter, including CVI Holdings LLC, Millennium Management LLC, OMERS ADMINISTRATION Corp, Schwab Charles Investment Management Inc., Mackay Shields LLC, Hikari Power Ltd and MetLife Investment Advisors LLC. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.
How do I buy shares of Synergy Pharmaceuticals?
Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synergy Pharmaceuticals' stock price today?
One share of SGYP stock can currently be purchased for approximately $1.86.
How big of a company is Synergy Pharmaceuticals?
Synergy Pharmaceuticals has a market capitalization of $446.60 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.
How can I contact Synergy Pharmaceuticals?
Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]
MarketBeat Community Rating for Synergy Pharmaceuticals (SGYP)
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
